

REMARKS

I. Status of Claims

Claims 25, 30 and 31 are pending in the application, as the remaining claims having been canceled. Claim 25 is now amended. Claims 25, 30 and 31 stand rejected under 35 U.S.C. §102(b) over Liliemark *et al.*, alone or in view of Hotte *et al.* The specific grounds for rejection, and applicants' response thereto, are set out in detail below.

II. Rejections Under 35 U.S.C. §102(b)

The examiner rejects all claims as anticipated by Liliemark *et al.*, alone or in view of Hotte *et al.* It is the examiner's position that AML and ALL constitute cancers in which hypercalcemia (and presumably bone destruction) occurs. Since such patients have allegedly been treated with 6-TG, the examiner finds the primary reference anticipatory.

Applicants traverse the rejection but, in the interest of advancing the prosecution, the claims have been amended to recite that the cancers to be treated are those that express PTH-rP. Support for the amendment can be found at pages 10-11 of the specification. Since neither AML nor ALL expresses PTH-rP, this recitation excludes the teachings of Liliemark. As such, it is believed that the claims as presented for reconsideration are novel and non-obvious. Withdrawal of the rejection is therefore respectfully requested.


III. Conclusion

In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance, and an early notification to that effect is earnestly solicited. The examiner is invited

to contact the undersigned at the telephone number listed below with any questions, comments or suggestions relating to the referenced patent application.

Please date stamp and return the enclosed postcard as evidence of receipt.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: April 4, 2005